Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.4 , No. 4, Publication Date: Aug. 3, 2017, Page: 30-37
 patients (ECP) (T1-4N0-2M0) was realized. METHODS: We analyzed data of 499 consecutive ECP (age=56.3±8.9 years; tumor size=6.3±3.4 cm) radically operated and monitored in 1975-2017 (m=365, f=134; esophagogastrectomies (EG) Garlock=280, EG Lewis=219, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=147; adenocarcinoma=284, squamous=205, mix=10; T1=92, T2=113, T3=171, T4=123; N0=234, N1=69, N2=196; G1=140, G2=123, G3=236; early EC=73, invasive=426; only surgery=382, adjuvant chemoimmunoradiotherapy-AT=117: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1763.2±2213.7 days and cumulative 5-year survival (5YS) reached 47.3%, 10 years – 40.7%, 20 years – 29.8%. 148 ECP lived more than 5 years (LS=4382.9±2551 days), 80 ECP – more than 10 years (LS=6027.2±2445.6 days). 223 ECP died because of EC (LS=630.2±320.5 days). AT significantly improved 5YS (67.7% vs. 43.1%) (P=0.00002 by log-rank test). Cox modeling displayed (Chi2=283.82, df=18, P=0.0000) that 5YS of ECP significantly depended on: phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells and blood cells subpopulations), G, age, AT, localization, blood cells, prothrombin index, coagulation time, residual nitrogen (P=0.000-0.048). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT N0--N12 (rank=1), PT early-invasive EC (rank=2), T (3), AT (4), prothrombin index (5), glucose (6), healthy cells/CC (7), thrombocytes/CC (8), erythrocytes/CC (9), segmented neutrophils/CC (10), lymphocytes/CC (11), monocytes/CC (12). Correct prediction of 5YS was 100% by neural networks computing. CONCLUSIONS: Optimal management for ECP are: 1) screening and early detection of EC; 2) availability of experienced thoracoabdominal surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for ECP with unfavorable prognosis.&picture=http://www.aascit.org/aascit/decorators/img/journal/906.jpg)
| [1] | Oleg Kshivets, Surgery Department, Roshal Hospital, Roshal, Moscow, Russia. |
OBJECTIVE: Search of best management for esophageal cancer (EC) patients (ECP) (T1-4N0-2M0) was realized. METHODS: We analyzed data of 499 consecutive ECP (age=56.3±8.9 years; tumor size=6.3±3.4 cm) radically operated and monitored in 1975-2017 (m=365, f=134; esophagogastrectomies (EG) Garlock=280, EG Lewis=219, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=147; adenocarcinoma=284, squamous=205, mix=10; T1=92, T2=113, T3=171, T4=123; N0=234, N1=69, N2=196; G1=140, G2=123, G3=236; early EC=73, invasive=426; only surgery=382, adjuvant chemoimmunoradiotherapy-AT=117: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1763.2±2213.7 days and cumulative 5-year survival (5YS) reached 47.3%, 10 years – 40.7%, 20 years – 29.8%. 148 ECP lived more than 5 years (LS=4382.9±2551 days), 80 ECP – more than 10 years (LS=6027.2±2445.6 days). 223 ECP died because of EC (LS=630.2±320.5 days). AT significantly improved 5YS (67.7% vs. 43.1%) (P=0.00002 by log-rank test). Cox modeling displayed (Chi2=283.82, df=18, P=0.0000) that 5YS of ECP significantly depended on: phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells and blood cells subpopulations), G, age, AT, localization, blood cells, prothrombin index, coagulation time, residual nitrogen (P=0.000-0.048). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT N0--N12 (rank=1), PT early-invasive EC (rank=2), T (3), AT (4), prothrombin index (5), glucose (6), healthy cells/CC (7), thrombocytes/CC (8), erythrocytes/CC (9), segmented neutrophils/CC (10), lymphocytes/CC (11), monocytes/CC (12). Correct prediction of 5YS was 100% by neural networks computing. CONCLUSIONS: Optimal management for ECP are: 1) screening and early detection of EC; 2) availability of experienced thoracoabdominal surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for ECP with unfavorable prognosis.
Keywords
Esophageal Cancer, Management, Optimization
Reference
| [01] | Graham AJ, Shrive FM, Ghali WA, Manns BJ, Grondin SC, Finley RJ, Clifton J. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007 Apr; 83 (4): 1257-64. |
| [02] | Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007 Mar; 8 (3): 226-34. |
| [03] | Kshivets O. Expert system in diagnosis and prognosis of malignant neoplasms. Dissertation for Sc. D., Tomsk, 1995: 639pp. |
| [04] | Morozow V. G., Chavinson V. C. Isolation, refinement and identification of immunomodulated polypeptide from calf and human thymus. Biochemistry, 1981; 9: 1652-59. |
| [05] | Odom-Maryon T. Biostatistical methods in oncology. Cancer management: A multidisciplinary approach. 1st ed. Huntington, NY: PRP Inc., 1996: 788-802. |
| [06] | Mirkin B. G. A sequential fitting procedure for linear data analysis models. J Classification 1990; 7: 167-196. |
| [07] | Joreskog K. G., Sorbom D. Recent development in structural equation modeling. J Marketing Research 1982; 19: 404-416. |
| [08] | Bostwick D. G., Burke H. B. Prediction of individual patient outcome in cancer: comparison of artificial neural networks and Kaplan-Meier methods. Cancer. 2001; 91 (8): 1643-1646. |
| [09] | Husmeier D. The Bayesian evidence scheme for regularizing probability-density estimating neural networks. Neural Comput. 2000; 12 (11): 2685-2717. |
| [10] | Kshivets O. Optimization of diagnosis process for patients with malignant neoplasms. Dissertation for PhD. St. Petersburg, 1992: 354 pp. |
| [11] | Chernousov A. F., Bogopolsky P. M., Kurbanov F. S. Esophageal surgery. M.: Moscow Publishers, 2000: 352 pp. |
| [12] | D'Journo XB, Doddoli C, Michelet P, Loundou A, Trousse D, Giudicelli R, Fuentes PA, Thomas PA. Transthoracic esophagectomy for adenocarcinoma of the oesophagus: standard versus extended two-field mediastinal lymphadenectomy? Eur J Cardiothorac Surg. 2005 Apr; 27 (4): 697-704. |
| [13] | Stilidi I, Davydov M, Bokhyan V, Suleymanov E. Subtotal esophagectomy with extended 2-field lymph node dissection for thoracic esophageal cancer. Eur J Cardiothorac Surg. 2003 Mar; 23 (3): 415-20. |
| [14] | Lerut T, Coosemans W, Decker G, De Leyn P, Moons J, Nafteux P, Van Raemdonck D. Diagnosis and therapy in advanced cancer of the esophagus and the gastroesophageal junction. Curr Opin Gastroenterol. 2006 Jul; 22 (4): 437-41. |
| [15] | Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002 Aug; 82 (4): 729-46. |
| [16] | Luketich JD, Schauer P, Urso K, Kassis E, Ferson P, Keenan R, Landreneau R. Future directions in esophageal cancer. Chest. 1998 Jan; 113 (1 Suppl): 120S-122S. |
| [17] | Yano T., Sugio K., Yamazaki K., et al. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer 1999; 26: 143-8. |
| [18] | Kshivets O. Immune cell and humoral circuit in prediction of non-small cell lung cancer patients survival after complete resections. Journal of Tumor Marker Oncology 2001; 16 (2): 161-174. |
